Roleira Fernanda M F, Costa Saul C, Gomes Ana R, Varela Carla L, Amaral Cristina, Augusto Tiago V, Correia-da-Silva Georgina, Romeo Isabella, Costa Giosuè, Alcaro Stefano, Teixeira Natércia, Tavares-da-Silva Elisiário J
Univ Coimbra, CIEPQPF, FFUC, Laboratory of Pharmaceutical Chemistry, Azinhaga de Santa Comba, Pólo III - Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal.
Univ Coimbra, FFUC, Laboratory of Pharmaceutical Chemistry, Azinhaga de Santa Comba, Pólo III - Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal.
Bioorg Chem. 2023 Feb;131:106286. doi: 10.1016/j.bioorg.2022.106286. Epub 2022 Nov 23.
In this work, new steroidal aromatase inhibitors (AIs) were designed, synthesized, and tested. In one approach, C-ring substituted steroids namely those functionalized at C-11 position with an α or β hydroxyl group or with a carbonyl group as well as C-9/C-11 steroidal olefins and epoxides were studied. It was found that the carbonyl group at C-11 is more beneficial for aromatase inhibition than the hydroxyl group, and that the C-ring epoxides were more potent than the C-ring olefins, leading to the discovery of a very strong AI, compound 7, with an IC of 0.011 μM, better than Exemestane, the steroidal AI in clinical use, which presents an IC of 0.050 μM. In another approach, we explored the biological activity of A-ring C-1/C-2 steroidal olefins and epoxides in relation to aromatase inhibition and compared it with the biological activity of C-ring C-9/C-11 steroidal olefins and epoxides. On the contrary to what was observed for the C-ring olefins and epoxides, the A-ring epoxides were less potent than A-ring olefins. Finally, the effect of 7β-methyl substitution on aromatase inhibition was compared with 7α-methyl substitution, showing that 7β-methyl is better than 7α-methyl substitution. Molecular modelling studies showed that the 7β-methyl on C-7 seems to protrude into the opening to the access channel of aromatase in comparison to the 7α-methyl. This comparison led to find the best steroidal AI (12a) of this work with IC of 0.0058 μM. Compound 12a showed higher aromatase inhibition capacity than two of the three AIs currently in clinical use.
在这项工作中,设计、合成并测试了新型甾体芳香酶抑制剂(AIs)。在一种方法中,研究了C环取代甾体,即那些在C-11位被α或β羟基或羰基官能化的甾体,以及C-9/C-11甾体烯烃和环氧化物。研究发现,C-11位的羰基比羟基对芳香酶抑制更有益,并且C环环氧化物比C环烯烃更有效,从而发现了一种非常强效的AI,化合物7,其IC50为0.011 μM,优于临床使用的甾体AI依西美坦,依西美坦的IC50为0.050 μM。在另一种方法中,我们探索了A环C-1/C-2甾体烯烃和环氧化物与芳香酶抑制相关的生物活性,并将其与C环C-9/C-11甾体烯烃和环氧化物的生物活性进行了比较。与C环烯烃和环氧化物的情况相反,A环环氧化物的效力低于A环烯烃。最后,比较了7β-甲基取代和7α-甲基取代对芳香酶抑制的影响,结果表明7β-甲基取代优于7α-甲基取代。分子模拟研究表明,与7α-甲基相比,C-7位的7β-甲基似乎突出到芳香酶进入通道的开口处。这种比较导致发现了这项工作中最佳的甾体AI(12a),其IC50为0.0058 μM。化合物12a显示出比目前临床使用的三种AI中的两种更高的芳香酶抑制能力。